Celltrion Pharm Inc Market Cap ($1.08 Billion)
Market Cap & Net Worth: Celltrion Pharm Inc (068760)
Celltrion Pharm Inc market cap. Celltrion Pharm Inc (KQ:068760) has a market capitalization of $1.08 Billion (₩1.59 Trillion) as of October 31, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #8240 globally and #206 in its home market, demonstrating a -5.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Celltrion Pharm Inc's stock price ₩36650.00 by its total outstanding shares 43422933 (43.42 Million).
Celltrion Pharm Inc Market Cap History (2015–2026)
Celltrion Pharm Inc market cap history from 2015 to 2026. Data shows growth from $397.62 Million to $1.08 Billion (12.35% CAGR). Check today's stock price for Celltrion Pharm Inc for real-time trading data and today's change.
Index Memberships
Celltrion Pharm Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$208.91 Billion | 0.52% | #40 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$208.91 Billion | 0.52% | #40 of 1384 |
Weight: Celltrion Pharm Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Celltrion Pharm Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Celltrion Pharm Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 068760 operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.00x
Celltrion Pharm Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.08x
Celltrion Pharm Inc's market cap is 0.08 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $397.62 Million | $74.73 Billion | $6.73 Billion | 0.01x | 0.06x |
| 2016 | $566.94 Million | $104.81 Billion | $2.92 Billion | 0.01x | 0.19x |
| 2017 | $1.48 Billion | $135.86 Billion | $2.71 Billion | 0.01x | 0.55x |
| 2018 | $1.54 Billion | $146.88 Billion | -$9.39 Billion | 0.01x | N/A |
| 2019 | $1.01 Billion | $173.51 Billion | $8.60 Billion | 0.01x | 0.12x |
| 2020 | $6.18 Billion | $233.57 Billion | $20.94 Billion | 0.03x | 0.30x |
| 2021 | $3.32 Billion | $398.74 Billion | $34.58 Billion | 0.01x | 0.10x |
| 2022 | $1.87 Billion | $386.04 Billion | $25.96 Billion | 0.00x | 0.07x |
| 2023 | $2.71 Billion | $388.79 Billion | $21.26 Billion | 0.01x | 0.13x |
| 2024 | $1.67 Billion | $477.84 Billion | $21.97 Billion | 0.00x | 0.08x |
Competitor Companies of 068760 by Market Capitalization
Companies near Celltrion Pharm Inc in the global market cap rankings as of October 31, 2026. See net asset quality index of Celltrion Pharm Inc to understand what proportion of total assets are financed by equity.
Key companies related to Celltrion Pharm Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Celltrion Pharm Inc (2015–2026)
Market capitalization of Celltrion Pharm Inc from 2015 to today. Between 2015 and today, Celltrion Pharm Inc's market cap moved from $397.62 Million to $ 1.08 Billion, with a yearly change of 12.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩1.08 Billion | -36.81% |
| 2025 | ₩1.71 Billion | +2.29% |
| 2024 | ₩1.67 Billion | -38.50% |
| 2023 | ₩2.71 Billion | +44.71% |
| 2022 | ₩1.87 Billion | -43.53% |
| 2021 | ₩3.32 Billion | -46.30% |
| 2020 | ₩6.18 Billion | +511.49% |
| 2019 | ₩1.01 Billion | -34.19% |
| 2018 | ₩1.54 Billion | +3.76% |
| 2017 | ₩1.48 Billion | +161.19% |
| 2016 | ₩566.94 Million | +42.59% |
| 2015 | ₩397.62 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Celltrion Pharm Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.08 Billion USD |
| MoneyControl | $1.08 Billion USD |
| MarketWatch | $1.08 Billion USD |
| marketcap.company | $1.08 Billion USD |
| Reuters | $1.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Celltrion Pharm Inc
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals a… Read more